AC Immune (NASDAQ:ACIU) Short Interest Up 94.4% in December
by Amy Steele · The Cerbat GemAC Immune (NASDAQ:ACIU – Get Free Report) was the recipient of a large increase in short interest during the month of December. As of December 15th, there was short interest totaling 3,593,227 shares, an increase of 94.4% from the November 30th total of 1,848,164 shares. Based on an average daily volume of 2,209,361 shares, the days-to-cover ratio is currently 1.6 days. Approximately 3.8% of the shares of the company are sold short. Approximately 3.8% of the shares of the company are sold short. Based on an average daily volume of 2,209,361 shares, the days-to-cover ratio is currently 1.6 days.
Institutional Trading of AC Immune
Hedge funds have recently modified their holdings of the company. Private Advisor Group LLC bought a new stake in shares of AC Immune during the third quarter valued at approximately $48,000. Sei Investments Co. acquired a new stake in AC Immune during the second quarter worth $51,000. Susquehanna International Group LLP bought a new stake in AC Immune in the 3rd quarter valued at $63,000. Assenagon Asset Management S.A. acquired a new position in shares of AC Immune in the 3rd quarter valued at $549,000. Finally, Acadian Asset Management LLC raised its stake in shares of AC Immune by 87.1% in the 1st quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock valued at $679,000 after buying an additional 172,796 shares in the last quarter. Institutional investors own 51.36% of the company’s stock.
Analyst Ratings Changes
ACIU has been the topic of several analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of AC Immune in a report on Wednesday, October 8th. BTIG Research reiterated a “buy” rating and issued a $8.00 target price on shares of AC Immune in a research note on Tuesday, November 4th. Finally, Zacks Research raised shares of AC Immune from a “strong sell” rating to a “hold” rating in a research report on Tuesday, September 9th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $10.00.
Check Out Our Latest Analysis on AC Immune
AC Immune Price Performance
NASDAQ:ACIU opened at $3.13 on Monday. AC Immune has a one year low of $1.43 and a one year high of $4.00. The company has a fifty day moving average price of $3.10 and a 200 day moving average price of $2.63. The stock has a market cap of $314.28 million, a P/E ratio of -3.73 and a beta of 1.60.
AC Immune (NASDAQ:ACIU – Get Free Report) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.02. AC Immune had a negative net margin of 1,642.89% and a negative return on equity of 84.32%. The company had revenue of $1.18 million for the quarter, compared to the consensus estimate of $0.81 million. As a group, equities research analysts anticipate that AC Immune will post -0.62 EPS for the current year.
AC Immune Company Profile
AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.
Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.